LCTX - Lineage Cell Therapeutics Inc Stock Price, Fair Value and News

1.09USD+0.03 (+2.83%)Delayed

Market Summary

USD1.09+0.03

Delayed

2.83%

LCTX Stock Price

View Fullscreen

LCTX RSI Chart

LCTX Valuation

Market Cap

205.8M

Price/Earnings (Trailing)

-8.7

Price/Sales (Trailing)

25.71

EV/EBITDA

-6.89

Price/Free Cashflow

-8.71

LCTX Price/Sales (Trailing)

LCTX Profitability

Operating Margin

91.88%

EBT Margin

-295.30%

Return on Equity

-33.32%

Return on Assets

-21.81%

Free Cashflow Yield

-11.48%

LCTX Fundamentals

LCTX Revenue

Revenue (TTM)

8.0M

Rev. Growth (Yr)

-39.48%

Rev. Growth (Qtr)

-30.84%

LCTX Earnings

Earnings (TTM)

-23.7M

Earnings Growth (Yr)

-49.63%

Earnings Growth (Qtr)

-37.01%

Breaking Down LCTX Revenue

Last 7 days

-6.8%

Last 30 days

-15.5%

Last 90 days

-3.5%

Trailing 12 Months

-18.7%

How does LCTX drawdown profile look like?

LCTX Financial Health

Current Ratio

2.71

LCTX Investor Care

Shares Dilution (1Y)

10.94%

Diluted EPS (TTM)

-0.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	8.0M	0	0	0
2023	11.9M	10.5M	8.8M	8.9M
2022	5.6M	10.1M	13.0M	14.7M
2021	666.0K	684.0K	751.0K	445.0K
2020	678.0K	0	0	0
2019	545.0K	322.0K	256.0K	257.0K
2018	2.3M	2.3M	691.0K	691.0K
2017	4.9M	3.8M	2.8M	1.8M
2016	7.0M	6.5M	6.1M	5.9M
2015	4.5M	5.4M	6.3M	5.9M
2014	4.1M	4.0M	4.4M	4.4M
2013	3.3M	3.4M	3.0M	3.6M
2012	4.2M	4.4M	4.0M	3.5M
2011	3.8M	3.8M	4.2M	4.4M
2010	0	2.5M	3.1M	3.7M
2009	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lineage Cell Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 11, 2024	samuel george a. iii	acquired	-	-	6,076	general counsel/secretary
Feb 11, 2024	samuel george a. iii	sold (taxes)	-2,689	1.08	-2,490	general counsel/secretary
Feb 11, 2024	culley brian m	sold (taxes)	-13,830	1.08	-12,806	president and ceo
Feb 11, 2024	culley brian m	acquired	-	-	31,249	president and ceo
Feb 08, 2024	bailey don m	bought	100,001	1.04	96,155	-
Feb 06, 2024	broadwood partners, l.p.	bought	-	-	-	-
Feb 06, 2024	broadwood partners, l.p.	bought	7,000,000	1.04	6,730,770	-
Dec 29, 2023	jayasuriya anula	bought	10,900	1.09	10,000	-
Feb 11, 2023	culley brian m	acquired	-	-	31,249	president and ceo
Feb 11, 2023	samuel george a. iii	sold (taxes)	-3,345	1.35	-2,478	general counsel/secretary

Which funds bought or sold LCTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-36.1	-23,668	155,104	-%
May 16, 2024	Beacon Capital Management, LLC	unchanged	-	4,500	22,200	-%
May 16, 2024	COMERICA BANK	added	84,745	370,115	370,437	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	-4,063	19,745	-%
May 15, 2024	BARCLAYS PLC	reduced	-48.76	-61,000	139,000	-%
May 15, 2024	Royal Bank of Canada	reduced	-98.24	-185,000	4,000	-%
May 15, 2024	Prescott General Partners LLC	unchanged	-	722,221	2,740,740	0.15%
May 15, 2024	DEUTSCHE BANK AG\	reduced	-1.96	27,580	110,850	-%
May 15, 2024	STATE STREET CORP	added	3.84	936,965	3,222,270	-%
May 15, 2024	WELLINGTON MANAGEMENT GROUP LLP	new	-	691,966	691,966	-%

Are Funds Buying or Selling LCTX?

Are funds buying LCTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LCTX

No. of Funds

Unveiling Lineage Cell Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 08, 2024	broadwood partners, l.p.	22.1%	0	SC 13D/A
Jul 08, 2022	blackrock inc.	2.2%	3,755,757	SC 13G
Mar 25, 2022	broadwood partners, l.p.	20.6%	0	SC 13D/A
Feb 04, 2022	blackrock inc.	5.9%	10,008,510	SC 13G
Mar 16, 2021	broadwood partners, l.p.	21.0%	0	SC 13D/A
Feb 14, 2020	greenbelt corp /ny	0.70%	1,043,346	SC 13D/A

Recent SEC filings of Lineage Cell Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	EFFECT	EFFECT
May 14, 2024	424B5	Prospectus Filed
May 14, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Mar 22, 2024	424B5	Prospectus Filed
Mar 22, 2024	8-K	Current Report

Peers (Alternatives to Lineage Cell Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Lineage Cell Therapeutics Inc News

Latest updates

Lineage Cell Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-30.8%	1,444,000	2,088,000	1,246,000	3,225,000	2,386,000	1,915,000	2,998,000	4,553,000	5,237,000	208,000	68,000	71,000	98,000	514,000	1,000	53,000	110,000	93,000	-	119,000	333,000
Cost Of Revenue	-61.7%	98,000	256,000	169,000	127,000	119,000	102,000	235,000	215,000	176,000	204,000	985,000	125,000	112,000	94,000	123,000	114,000	107,000	68,000	52,000	35,000	106,000
Gross Profit	-100.0%	-	1,832,000	1,077,000	3,098,000	2,267,000	1,813,000	2,763,000	4,338,000	5,061,000	964,000	1,285,000	387,000	279,000	420,000	1,118,000	453,000	672,000	860,000	706,000	947,000	2,441,000
Operating Expenses	-100.0%	-	8,194,000	7,782,000	8,122,000	8,909,000	8,452,000	8,014,000	8,572,000	11,457,000	29,202,000	8,128,000	7,467,000	7,329,000	7,858,000	7,990,000	8,875,000	11,493,000	13,621,000	10,813,000	11,304,000	11,585,000
S&GA Expenses	-100.0%	-	4,288,000	4,041,000	4,249,000	4,724,000	4,347,500	4,422,000	5,270,000	8,469,000	4,424,000	5,317,000	4,536,000	3,935,000	4,519,000	4,504,000	4,609,000	6,258,000	8,660,000	7,087,000	6,422,000	5,227,000
R&D Expenses	-22.9%	3,010,000	3,906,000	3,741,000	3,873,000	4,185,000	4,104,500	3,592,000	3,302,000	2,988,000	24,778,000	2,811,000	2,931,000	3,394,000	3,339,000	3,486,000	4,266,000	5,235,000	4,961,000	3,780,000	4,882,000	6,358,000
EBITDA Margin	-15.4%	-2.93	-2.54	-2.69	-2.09	-2.02	-1.72	-3.57	-4.97	-8.64	-95.74	-18.07	-18.11	-	-	-	-	-	-	-	-	-
Interest Expenses	100.2%	2,000	-1,215,000	433,000	382,000	410,000	-422,500	384,000	51,000	1,000	2,500	1,000	-3,000	2,000	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-1,803,000	-41,000	541,000	-	-	-	-1,012,000	-	-	-	-	-	-	4,384,000	5,520,977	-	-
Earnings Before Taxes	-39.1%	-6,558,000	-4,714,000	-7,158,000	-5,203,000	-6,207,000	-6,362,000	-5,575,000	-6,782,000	-7,093,000	-28,010,000	-8,846,000	-4,965,000	-1,448,000	-8,428,000	-5,340,000	-17,506,000	-31,300,000	34,912,000	-45,330,000	66,544,000	-4,646,000
EBT Margin	-13.5%	-2.95	-2.60	-2.84	-2.22	-2.10	-1.76	-3.65	-5.04	-8.76	-97.23	-19.01	-19.56	-	-	-	-	-	-	-	-	-
Net Income	-37.0%	-6,542,000	-4,775,000	-7,110,000	-5,229,000	-4,372,000	-6,354,000	-6,069,000	-6,763,000	-7,087,000	-28,992,000	-7,823,000	-4,788,000	-1,416,000	-8,399,000	-4,482,000	-16,505,000	-30,032,000	39,310,000	-44,952,000	66,725,000	-4,215,000
Net Income Margin	-23.1%	-2.96	-2.40	-2.63	-2.09	-1.99	-1.79	-3.76	-5.03	-8.72	-96.67	-15.97	-17.44	-	-	-	-	-	-	-	-	-
Free Cashflow	4.7%	-5,821,000	-6,110,000	-5,176,000	-6,524,000	-11,430,000	-8,287,000	-5,766,000	-7,159,000	21,858,000	-6,019,000	-4,902,000	-5,545,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	7.4%	108	101	106	112	113	124	131	136	145	175	131	135	128	108	103	112	119	125	133	152	184
Current Assets	18.9%	46.00	38.00	43.00	48.00	50.00	60.00	69.00	74.00	82.00	112	68.00	72.00	65.00	44.00	40.00	46.00	52.00	58.00	62.00	20.00	31.00
Cash Equivalents	24.5%	44.00	35.00	31.00	34.00	15.00	11.00	25.00	71.00	78.00	56.00	61.00	62.00	56.00	33.00	33.00	13.00	10.00	9.00	14.00	8.00	18.00
Net PPE	-55.9%	2.00	5.00	5.00	5.00	6.00	6.00	5.00	4.00	5.00	5.00	5.00	5.00	5.00	6.00	5.00	7.00	8.00	8.00	9.00	9.00	9.00
Goodwill	0%	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	13.00	13.00	13.00
Liabilities	-3.9%	37.00	39.00	39.00	40.00	44.00	52.00	54.00	54.00	59.00	84.00	12.00	11.00	11.00	13.00	13.00	14.00	14.00	14.00	17.00	20.00	22.00
Current Liabilities	-6.0%	17.00	18.00	16.00	16.00	17.00	19.00	23.00	25.00	25.00	47.00	9.00	7.00	7.00	8.00	8.00	8.00	7.00	6.00	6.00	8.00	9.00
Shareholder's Equity	11.9%	71.00	63.00	68.00	71.00	69.00	73.00	78.00	81.00	85.00	91.00	120	124	117	95.00	90.00	98.00	105	111	116	132	161
Retained Earnings	-1.7%	-391	-384	-380	-372	-367	-363	-357	-350	-344	-337	-308	-300	-295	-294	-296	-288	-281	-273	-268	-252	-222
Shares Outstanding	7.9%	189	175	175	174	170	170	170	170	170	169	163	161	-	-	-	-	-	-	-	-	-
Minority Interest	-1.1%	-1.41	-1.40	-1.46	-1.41	-1.43	-1.40	-1.39	-1.35	-1.33	-1.32	-1.12	-1.11	-1.10	-1.07	-1.08	-1.75	-1.74	-1.71	-1.64	-1.63	-1.61
Float	-	-	-	-	186	-	-	-	201	-	-	-	357	-	-	-	94.00	-	-	-	119	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	3.9%	-5,783	-6,019	-5,037	-6,268	-11,242	-8,303	-5,480	-7,062	21,904	-5,873	-4,848	-5,416	-7,424	-5,641	-4,847	-4,239	-5,026	-5,523	-7,443	-9,667	-9,314
Share Based Compensation	9.7%	1,163	1,060	1,269	1,280	1,031	959	987	1,235	1,106	918	1,144	919	539	494	501	606	626	619	759	762	1,440
Cashflow From Investing	-100.4%	-38.00	9,742	2,122	19,159	15,426	-5,102	-40,914	-97.00	-46.00	-146	-68.00	-115	10,074	902	178	6,702	5,256	720	13,485	-194	2,946
Cashflow From Financing	107953.8%	14,021	-13.00	807	5,628	1.00	122	964	33.00	513	954	3,719	11,294	20,963	4,814	24,558	503	-10.00	-5.00	79.00	-63.00	606

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LCTX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues [Abstract]
Total revenues	$ 1,444	$ 2,386
OPERATING EXPENSES:
Cost of sales	98	119
Research and development	3,010	4,185
General and administrative	4,997	4,724
Total operating expenses	8,105	9,028
Loss from operations	(6,661)	(6,642)
OTHER INCOME (EXPENSES):
Interest income, net	462	410
(Loss) gain on marketable equity securities, net	(5)	40
Foreign currency transaction gain/(loss), net	(354)	(472)
Other income	0	457
Total other income (expenses), net	103	435
Loss before net income tax benefit	(6,558)	(6,207)
Provision for income tax benefit	0	1,803
NET LOSS	(6,558)	(4,404)
Net loss attributable to noncontrolling interest	16	32
NET LOSS ATTRIBUTABLE TO LINEAGE CELL THERAPEUTICS, INC.	$ (6,542)	$ (4,372)
Net loss per common share attributable to Lineage
Basic	$ (0.04)	$ (0.03)
Diluted	$ (0.04)	$ (0.03)
Weighted-average common shares used to compute basic and diluted net loss per common share
Basic	182,909	170,127
Diluted	182,909	170,127
Collaboration Revenues [Member]
Revenues [Abstract]
Total revenues	$ 1,187	$ 2,121
Royalties, License and Other Revenues [Member]
Revenues [Abstract]
Total revenues	$ 257	$ 265

LCTX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

CURRENT ASSETS

Cash and cash equivalents

$ 43,576

$ 35,442

Marketable securities

Accounts receivable, net

745

Prepaid expenses and other current assets

2,018

2,204

Total current assets

45,716

38,441

NONCURRENT ASSETS

Property and equipment, net

2,104

2,245

Operating lease right-of-use assets

2,855

2,522

Deposits and other long-term assets

596

577

Goodwill

^[1]

10,672

Intangible assets, net

46,540

46,562

TOTAL ASSETS

108,483

101,019

CURRENT LIABILITIES

Accounts payable and accrued liabilities

5,683

6,270

Operating lease liabilities, current portion

1,052

830

Finance lease liabilities, current portion

Deferred revenues, current portion

10,106

10,808

Total current liabilities

16,890

17,960

LONG-TERM LIABILITIES

Deferred tax liability

273

Deferred revenues, net of current portion

18,177

18,693

Operating lease liabilities, net of current portion

2,074

1,979

Finance lease liabilities, net of current portion

TOTAL LIABILITIES

37,493

38,996

Commitments and contingencies (Note 13)

SHAREHOLDERS' EQUITY

Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of March 31, 2024 and December 31, 2023

Common shares, no par value, 450,000 shares authorized as of March 31, 2024 and December 31, 2023; 188,754 and 174,987 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively

466,571

451,343

Accumulated other comprehensive loss

(2,771)

(3,068)

Accumulated deficit

(391,398)

(384,856)

Lineage's shareholders' equity

72,402

63,419

Noncontrolling deficit

(1,412)

(1,396)

Total shareholders’ equity

70,990

62,023

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$ 108,483

$ 101,019

[1]

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger, see Note 13 (Commitment and Contingencies) for further discussion on the Asterias Merger. To date, we have not recognized any goodwill impairment.

About Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

CEO	Mr. Brian M. Culley M.A., M.B.A.
WEBSITE	https://lineagecell.com
INDUSTRY	Biotechnology
EMPLOYEES	70

Lineage Cell Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Lineage Cell Therapeutics Inc? What does LCTX stand for in stocks?

LCTX is the stock ticker symbol of Lineage Cell Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lineage Cell Therapeutics Inc (LCTX)?

As of Fri May 17 2024, market cap of Lineage Cell Therapeutics Inc is 205.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LCTX stock?

You can check LCTX's fair value in chart for subscribers.

What is the fair value of LCTX stock?

You can check LCTX's fair value in chart for subscribers. The fair value of Lineage Cell Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lineage Cell Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LCTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lineage Cell Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether LCTX is over valued or under valued. Whether Lineage Cell Therapeutics Inc is cheap or expensive depends on the assumptions which impact Lineage Cell Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LCTX.

What is Lineage Cell Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LCTX's PE ratio (Price to Earnings) is -8.7 and Price to Sales (PS) ratio is 25.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LCTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lineage Cell Therapeutics Inc's stock?

In the past 10 years, Lineage Cell Therapeutics Inc has provided -0.062 (multiply by 100 for percentage) rate of return.